scholarly journals Family history of prostate cancer and prostate cancer risk in the Alpha‐Tocopherol, Beta‐Carotene Cancer Prevention (ATBC) Study

2008 ◽  
Vol 123 (5) ◽  
pp. 1154-1159 ◽  
Author(s):  
Jiyoung Ahn ◽  
Roxana Moslehi ◽  
Stephanie J. Weinstein ◽  
Kirk Snyder ◽  
Jarmo Virtamo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Family History ◽  
Cancer Risk ◽  
Cancer Prevention ◽  
Prostate Cancer Risk ◽  
Beta Carotene ◽  
Alpha Tocopherol ◽  
History Of ◽  
Atbc Study

scholarly journals Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha‐tocopherol, beta‐carotene cancer prevention (ATBC) study

2015 ◽  
Vol 137 (9) ◽  
pp. 2124-2132 ◽  
Author(s):  
Alison M. Mondul ◽  
Steven C. Moore ◽  
Stephanie J. Weinstein ◽  
Edward D. Karoly ◽  
Joshua N. Sampson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Cancer Prevention ◽  
Prospective Cohort ◽  
Prostate Cancer Risk ◽  
Beta Carotene ◽  
Alpha Tocopherol ◽  
Metabolomic Analysis ◽  
Atbc Study

scholarly journals Ruminant Fatty Acids and Prostate Cancer Risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study

2012 ◽  
Vol 21 (3) ◽  
pp. 560.1-560
Author(s):  
Wright M ◽  
Albanes D ◽  
Moser A ◽  
Snyder K ◽  
Virtamo J ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Fatty Acids ◽  
Cancer Risk ◽  
Cancer Prevention ◽  
Prostate Cancer Risk ◽  
Beta Carotene ◽  
Alpha Tocopherol ◽  
Prevention Study

scholarly journals Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Johanna Tolksdorf ◽  
Michael W. Kattan ◽  
Stephen A. Boorjian ◽  
Stephen J. Freedland ◽  
Karim Saba ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Family History ◽  
Cancer Risk ◽  
Risk Prediction ◽  
Prostate Biopsy ◽  
Prostate Cancer Risk ◽  
High Grade ◽  
Prediction Tools ◽  
History Of

Abstract Background Online clinical risk prediction tools built on data from multiple cohorts are increasingly being utilized for contemporary doctor-patient decision-making and validation. This report outlines a comprehensive data science strategy for building such tools with application to the Prostate Biopsy Collaborative Group prostate cancer risk prediction tool. Methods We created models for high-grade prostate cancer risk using six established risk factors. The data comprised 8492 prostate biopsies collected from ten institutions, 2 in Europe and 8 across North America. We calculated area under the receiver operating characteristic curve (AUC) for discrimination, the Hosmer-Lemeshow test statistic (HLS) for calibration and the clinical net benefit at risk threshold 15%. We implemented several internal cross-validation schemes to assess the influence of modeling method and individual cohort on validation performance. Results High-grade disease prevalence ranged from 18% in Zurich (1863 biopsies) to 39% in UT Health San Antonio (899 biopsies). Visualization revealed outliers in terms of risk factors, including San Juan VA (51% abnormal digital rectal exam), Durham VA (63% African American), and Zurich (2.8% family history). Exclusion of any cohort did not significantly affect the AUC or HLS, nor did the choice of prediction model (pooled, random-effects, meta-analysis). Excluding the lowest-prevalence Zurich cohort from training sets did not statistically significantly change the validation metrics for any of the individual cohorts, except for Sunnybrook, where the effect on the AUC was minimal. Therefore the final multivariable logistic model was built by pooling the data from all cohorts using logistic regression. Higher prostate-specific antigen and age, abnormal digital rectal exam, African ancestry and a family history of prostate cancer increased risk of high-grade prostate cancer, while a history of a prior negative prostate biopsy decreased risk (all p-values < 0.004). Conclusions We have outlined a multi-cohort model-building internal validation strategy for developing globally accessible and scalable risk prediction tools.

scholarly journals First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Zheng-Ju Ren ◽  
De-Hong Cao ◽  
Qin Zhang ◽  
Peng-Wei Ren ◽  
Liang-Ren Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Systematic Review ◽  
Family History ◽  
Cancer Risk ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
History Of

Abstract 2543: A family affair: Prostate cancer risk and family history of breast or prostate cancer

2016 ◽  
Author(s):  
Lauren E. Barber ◽  
Travis A. Gerke ◽  
Sarah C. Markt ◽  
Giovanni Parmigiani ◽  
Lorelei A. Mucci
Keyword(s):  
Prostate Cancer ◽  
Family History ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
History Of

scholarly journals Dutasteride and Prostate Cancer Risk: Does Family History of Prostate and/or Breast Cancers Influence the Number Needed to Treat? Results from REDUCE

2014 ◽  
Vol 2 (2) ◽  
pp. 31-36
Author(s):  
Jean-Alfred Thomas II ◽  
Leah Gerber ◽  
Robert J. Hamilton ◽  
Adriana C. Vidal ◽  
Daniel M. Moreira ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Family History ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Number Needed To Treat ◽  
Breast Cancers ◽  
History Of

scholarly journals Serum Metabolomic Response to Long-Term Supplementation withall-rac-α-Tocopheryl Acetate in a Randomized Controlled Trial

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Alison M. Mondul ◽  
Steven C. Moore ◽  
Stephanie J. Weinstein ◽  
Anne M. Evans ◽  
Edward D. Karoly ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Vitamin E ◽  
Cancer Prevention ◽  
Controlled Trial ◽  
Prostate Cancer Risk ◽  
Alpha Tocopherol ◽  
Tocopheryl Acetate ◽  
Metabolite Level ◽  
Randomized Controlled ◽  
Atbc Study

Background. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, a randomized controlled cancer prevention trial, showed a 32% reduction in prostate cancer incidence in response to vitamin E supplementation. Two other trials were not confirmatory, however.Objective. We compared the change in serum metabolome of the ATBC Study participants randomized to receive vitamin E to those who were not by randomly selecting 50 men from each of the intervention groups (50 mg/day all-rac-α-tocopheryl acetate (ATA), 20 mg/dayβ-carotene, both, placebo).Methods. Metabolomic profiling was conducted on baseline and follow-up fasting serum (Metabolon, Inc.).Results. After correction for multiple comparisons, five metabolites were statistically significantly altered (βis the change in metabolite level expressed as number of standard deviations on the log scale):α-CEHC sulfate (β=1.51,p=1.45×10-38),α-CEHC glucuronide (β=1.41,p=1.02×10-31),α-tocopherol (β=0.97,p=2.22×10-13),γ-tocopherol (β=-0.90,p=1.76×10-11), andβ-tocopherol (β=-0.73,p=9.40×10-8). Glutarylcarnitine, beta-alanine, ornithine, and N6-acetyllysine were also decreased by ATA supplementation (βrange 0.40 to −0.36), but not statistically significantly.Conclusions. Comparison of the observed metabolite alterations resulting from ATA supplementation to those in other vitamin E trials of different populations, dosages, or formulations may shed light on the apparently discordant vitamin E-prostate cancer risk findings.

Prostate cancer risk in U.S. blacks and whites with a family history of cancer

1995 ◽  
Vol 60 (3) ◽  
pp. 361-364 ◽  
Author(s):  
Richard B. Hayes ◽  
Jonathan M Liff ◽  
Linda M. Pottern ◽  
Raymond S. Greenberg ◽  
Janet B. Schoenberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Family History ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Family History Of Cancer ◽  
History Of ◽  
Blacks And Whites ◽  
History Of Cancer

FIRST-DEGREE FAMILY HISTORY OF PROSTATE CANCER AND CARRIER STATUS OF PROSTATE CANCER RISK ALLELES

2009 ◽  
Vol 181 (4S) ◽  
pp. 49-49
Author(s):  
Joshua J Meeks ◽  
Brian T Helfand ◽  
Stacy Loeb ◽  
Donghui Kan ◽  
Angela J Fought ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Family History ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Carrier Status ◽  
Risk Alleles ◽  
History Of
Sign in / Sign up

Export Citation Format

Share Document